Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

被引：152

作者：

Lacy, M. Q. ^{[1
]}

Hayman, S. R. ^{[1
]}

Gertz, M. A. ^{[1
]}

Short, K. D. ^{[1
]}

Dispenzieri, A. ^{[1
]}

Kumar, S. ^{[1
]}

Greipp, P. R. ^{[1
]}

Lust, J. A. ^{[1
]}

Russell, S. J. ^{[1
]}

Dingli, D. ^{[1
]}

Zeldenrust, S. ^{[1
]}

Fonseca, R. ^{[2
]}

Bergsagel, P. L. ^{[2
]}

Roy, V. ^{[3
]}

Mikhael, J. R. ^{[2
]}

Stewart, A. K. ^{[2
]}

Laumann, K.

Allred, J. B.

Mandrekar, S. J.

Rajkumar, S. V. ^{[1
]}

Buadi, F. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Coll Med, Rochester, MN 55905 USA

[2] Mayo Clin, Scottsdale, AZ USA

[3] Mayo Clin, Jacksonville, FL 32224 USA

来源：

LEUKEMIA | 2010年 / 24卷 / 11期

关键词：

mulitiple myeloma; immunomodulatory drugs; therapy; clinical trial; THALIDOMIDE ANALOGS; CYTOKINE PRODUCTION; IN-VIVO; STRATIFICATION; ANGIOGENESIS; INHIBITION; CRITERIA; ALPHA; CELLS;

D O I：

10.1038/leu.2010.190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in this group, we treated a cohort of lenalidomide refractory patients. Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly. Responses were assessed by the International Myeloma Working Group Criteria. Thirty-four patients were enrolled. The best response was very good partial response in 3 (9%), partial response (PR) in 8 (23%), best responses (MR) in 5 (15%), stable disease in 12 (35%) and progressive disease in 6 (18%), for an overall response rate of 47%. Of the 14 patients that were considered high risk, 8 (57%) had responses including 4 PR and 4 MR. The median time to response was 2 months and response duration was 9.1 months, respectively. The median overall survival was 13.9 months. Toxicity was primarily hematologic, with grade 3 or 4 toxicity seen in 18 patients (53%) consisting of anemia (12%), thrombocytopenia (9%) and neutropenia (26%). The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma. Leukemia (2010) 24, 1934-1939; doi:10.1038/leu.2010.190; published online 9 September 2010

引用

页码：1934 / 1939

页数：6

共 16 条

[1]

Corral LG, 1999, J IMMUNOL, V163, P380

[2] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[3] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[4] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[5] Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset [J].

Haslett, PAJ ;

Corral, LG ;

Albert, M ;

Kaplan, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1885-1892

[6] Novel therapies for multiple myeloma [J].

Hayashi, T ;

Hideshima, T ;

Anderson, KC .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) :10-17

[7] Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity [J].

Keifer, JA ;

Guttridge, DC ;

Ashburner, BP ;

Baldwin, AS .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) :22382-22387

[8] IMiDs: A novel class of immunomodulators [J].

Knight, R .

SEMINARS IN ONCOLOGY, 2005, 32 (04) :S24-S30

[9] Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines [J].

Kumar, Shaji K. ;

Mikhael, Joseph R. ;

Buadi, Francis K. ;

Dingli, David ;

Dispenzieri, Angela ;

Fonseca, Rafael ;

Gertz, Morie A. ;

Greipp, Philip R. ;

Hayman, Suzanne R. ;

Kyle, Robert A. ;

Lacy, Martha Q. ;

Lust, John A. ;

Reeder, Craig B. ;

Roy, Vivek ;

Russell, Stephen J. ;

Short, Kristen E. Detweiler ;

Stewart, A. Keith ;

Witzig, Thomas E. ;

Zeldenrust, Steven R. ;

Dalton, Robert J. ;

Rajkumar, S. Vincent ;

Bergsagel, P. Leif .

MAYO CLINIC PROCEEDINGS, 2009, 84 (12) :1095-1110

[10] Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [J].

Kyle, R. A. ;

Rajkumar, S. V. .

LEUKEMIA, 2009, 23 (01) :3-9

← 1 2 →